Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Advanced Life Sciences CEO Michael Flavin decided a pair of superiority trials was the best way to prove the efficacy of the company’s Restanza in community-acquired bacterial pneumonia, given the "stalemate" at FDA regarding the use of non-inferiority trials in antibiotics.
Advertisement

Related Content

FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.
Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report
Regulatory News, In Brief
Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Biomarker Guidance To Encompass More Than Biomarkers, FDA Says
FDA's Final PRO Guidance Grounds Policy With More Details
Advanced Life Sciences Restanza Blocked By New FDA Efficacy Criteria

Topics

Advertisement
UsernamePublicRestriction

Register

PS004533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel